![]() |
Name |
3-[(2R)-2-Hydroxy-3,3-dichloropropyl]-6,8-dihydroxy-1H-2-benzopyran-1-one
|
Molecular Formula | C12H10Cl2O5 | |
IUPAC Name* |
3-[(2R)-3,3-dichloro-2-hydroxypropyl]-6,8-dihydroxyisochromen-1-one
|
|
SMILES |
C1=C2C=C(OC(=O)C2=C(C=C1O)O)C[C@H](C(Cl)Cl)O
|
|
InChI |
InChI=1S/C12H10Cl2O5/c13-11(14)9(17)4-7-2-5-1-6(15)3-8(16)10(5)12(18)19-7/h1-3,9,11,15-17H,4H2/t9-/m1/s1
|
|
InChIKey |
OOPPUAGCTAYOTR-SECBINFHSA-N
|
|
Synonyms |
Desmethyldichlorodiaportin; 3-[(2R)-2-Hydroxy-3,3-dichloropropyl]-6,8-dihydroxy-1H-2-benzopyran-1-one
|
|
CAS | NA | |
PubChem CID | 24882465 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 305.11 | ALogp: | 2.7 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 87.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 19 | QED Weighted: | 0.758 |
Caco-2 Permeability: | -4.851 | MDCK Permeability: | 0.00003920 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.993 |
Human Intestinal Absorption (HIA): | 0.014 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.843 |
Blood-Brain-Barrier Penetration (BBB): | 0.047 | Plasma Protein Binding (PPB): | 88.01% |
Volume Distribution (VD): | 0.633 | Fu: | 13.41% |
CYP1A2-inhibitor: | 0.892 | CYP1A2-substrate: | 0.708 |
CYP2C19-inhibitor: | 0.032 | CYP2C19-substrate: | 0.28 |
CYP2C9-inhibitor: | 0.12 | CYP2C9-substrate: | 0.944 |
CYP2D6-inhibitor: | 0.051 | CYP2D6-substrate: | 0.24 |
CYP3A4-inhibitor: | 0.046 | CYP3A4-substrate: | 0.18 |
Clearance (CL): | 7.537 | Half-life (T1/2): | 0.851 |
hERG Blockers: | 0.034 | Human Hepatotoxicity (H-HT): | 0.232 |
Drug-inuced Liver Injury (DILI): | 0.183 | AMES Toxicity: | 0.092 |
Rat Oral Acute Toxicity: | 0.08 | Maximum Recommended Daily Dose: | 0.668 |
Skin Sensitization: | 0.668 | Carcinogencity: | 0.324 |
Eye Corrosion: | 0.024 | Eye Irritation: | 0.639 |
Respiratory Toxicity: | 0.813 |